Repro-Med Systems (OTCMKTS:REPR) and Regenicin (OTCMKTS:RGIN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
17.8% of Repro-Med Systems shares are owned by institutional investors. 40.0% of Repro-Med Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Repro-Med Systems and Regenicin’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Repro-Med Systems and Regenicin, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Repro-Med Systems has a beta of -0.8, indicating that its stock price is 180% less volatile than the S&P 500. Comparatively, Regenicin has a beta of 3.93, indicating that its stock price is 293% more volatile than the S&P 500.
Valuation & Earnings
This table compares Repro-Med Systems and Regenicin’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Repro-Med Systems||$17.35 million||3.52||$910,000.00||N/A||N/A|
Repro-Med Systems has higher revenue and earnings than Regenicin.
Repro-Med Systems beats Regenicin on 7 of the 8 factors compared between the two stocks.
Repro-Med Systems Company Profile
Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.
Regenicin Company Profile
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. Its development products include NovaDerm, a cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is based in Little Falls, New Jersey.
Receive News & Ratings for Repro-Med Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repro-Med Systems and related companies with MarketBeat.com's FREE daily email newsletter.